ArticleBioinformation2024
Impact of the COVID-19 pandemic on care delivery, follow-up and outcomes in chronic myeloid leukemia patients: An observational cohort study.
Article in Bioinformation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm that comprises a chronic phase. Therefore, it is of interest to evaluate the impact of care delivery and loss of follow-up or defaulted treatment due to the COVID-19 pandemic affecting the outcome in known chronic myeloid leukemia patients. Data was retrospectively retrieved and prospectively evaluated from the known and treated CML patients. A questionnaire was prepared for history. Bone marrow slides stained with Giemsa stain and multi-color flow cytometry were used for the evaluation of blast type in all blast crisis cases. A total of 961 new CML cases were reported, age range from 21 to 78 years, results were analyzed in three different cohort groups based on their time of diagnosis. Loss of follow-up was noticed mainly during the COVID-19 period and thereafter because of non-compliance. Data shows that about 53% of cases showed no hematological response and about 34% transformed into a CML blast crisis phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.